Topical pimecrolimus for skin disease other than atopic dermatitis

Bibliography

• GUPTA AK, CHOW M: Pimecrolimus: a review. J. Eur. Acad. Dermatol. Venereol. (2003) 17:493-503.
   PubMed Web of Science ®Google Scholar
• WOLFF K, STUETZ A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5:643-655.
   PubMed Web of Science ®Google Scholar
• DRAELOS Z, NAYAK A, PARISER D et al.: Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J. Am. Acad. Dermatol. (2005) 53:602-609.
   PubMed Web of Science ®Google Scholar
• MEINGASSNER JG, ASCHAUER H, STUETZ A, BLILLICH A: Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp. Dermatol. (2005) 14:752-757.
   PubMed Web of Science ®Google Scholar
• PAUL C, CORK M, ROSSI AB, PAPP KA, BARBIER N, DE PROST Y: Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated up to 2 years. Pediatrics. (2006) 117:118-125.
   PubMed Web of Science ®Google Scholar
• SUNDERKÖTTER C, WEISS JM, BEXTERMÖLLER R, LÖFFLER H, SCHNEIDER D: Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: Positive effects on major symptoms of atopic dermatitis and quality of life. J. Dtsch. Dermatol. Ges. (2006) 4:301-306.
   PubMedGoogle Scholar
• LUGER T, LAHFA M, FOLSTER-HOLST R et al.: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatol. Treat. (2004) 15:169-178.
   PubMedGoogle Scholar
• FONACIER L, SPERGEL J, CHARLESWORTH EN et al.: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. (2005) 115:1249-1253.
   PubMed Web of Science ®Google Scholar
• YAROSH DB, PENA AV, NAY SL, CANNING MT, BROWN DA: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol. (2005) 125:1220-1025.
   Google Scholar
• TRAN C, LUBBE J, SORG O et al.: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology (2005) 211:341-347.
   PubMed Web of Science ®Google Scholar
• DOELKER L, TRAN C, GKOMOUZAS A et al.: Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp. Dermatol. (2006) 15:342-346.
   PubMed Web of Science ®Google Scholar
• RING J, BARKER J, BEHRENDT H et al.: Review of the potential photo-cocarcinogenecity of topical calcineurin inhibitors. Position statement of the European Dermatology Forum. J. Eur. Acad. Dermatol. Venereol. (2005) 19:663-671.
   PubMed Web of Science ®Google Scholar
• BERGER TG, DUVIC M, VAN VOORHEES AS, FRIEDEN IJ: The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J. Am. Acad. Dermatol. (2006) 54:818-823.
   PubMed Web of Science ®Google Scholar
• CRUTCHFIELD CE III: Pimecrolimus: new treatment for seborrheic dermatitis. Cutis (2002) 70:207-208.
   PubMedGoogle Scholar
• BROWNELL I, QUAN LT, HSU S: Topical pimecrolimus in the treatment of seborrhoic dermatitis. Dermatology Online J. (2003) 9:13.
   PubMedGoogle Scholar
• RALLIS E, NASIOPOULOU A, KOUSKOUKIS C, KOUMANTAKI E: Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp. Clin. Res. (2004) 30:191-195.
   PubMedGoogle Scholar
• RIGOPOULOS D, IOANNIDES D, KALOGEROMITROS D, GREGORIOU S, KATSAMBAS A: Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical study. Br. J. Dermatol. (2004) 151:1071-1075.
   PubMed Web of Science ®Google Scholar
• HIGH WA, PANDYA AG: Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J. Am. Acad. Dermatol. (2006) 54:1083-1088.
   PubMed Web of Science ®Google Scholar
• BLACK RJ: Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin. Exp. Dermatol. (2005) 30:91-92.
   PubMedGoogle Scholar
• BELSITO DV, FOWLER JF Jr, MARKS JG Jr et al.: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis (2004) 73:31-38.
   PubMed Web of Science ®Google Scholar
• WARSHAW EM: Therapeutic options for chronic hand dermatitis. Dermatol. Therapy (2004) 17:240-250.
   PubMedGoogle Scholar
• COHEN DE, HEIDARY N: Treatment of irritant and allergic contact dermatitis. Dermatol. Therapy (2004) 17:334-340.
   PubMedGoogle Scholar
• WOLLINA U, ABDEL-NASER MB: Pharmacotherapy of pompholyx. Exp. Opin. Pharmacother. (2004) 5:1517-1522.
   PubMed Web of Science ®Google Scholar
• BUKHARI IA: Successful treatment of chronic persistant vesicular hand dermatitis with topical pimecrolimus. Saudi Med. J. (2005) 26:1989-1991.
   Google Scholar
• BRUCKNER AL, WESTON WL: Allergic contact dermatitis in children: a practical approach to management. Skin Therapy Lett. (2002) 7:3-5.
   PubMedGoogle Scholar
• KREUTER A, HOCHDORFER B, ALTMEYER P, GAMBICHLER T: Pimecrolimus 1% cream for perianal atopic dermatitis. Br. J. Dermatol. (2005) 152:186-187.
   Google Scholar
• LAZAROUS MC, KERDEL FA: Topical tacrolimus Protopic. Drugs Today (2002) 38:7-15.
   Google Scholar
• MROWIETZ U, GRAEBER M, BRÄUTIGAM M et al.: The novel ascomycin derivate SDZ ASM 981 is effective in psoriasis when used topically under occlusion. Br. J. Dermatol. (1998) 139:992-996.
   PubMed Web of Science ®Google Scholar
• GRIBETZ C, LING M, LEBWOHL M et al.: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. (2004) 51:731-738.
   PubMed Web of Science ®Google Scholar
• LEWKOWICZ D, GOTTLIEB AB: Pediatric psoriasis and psoriatic arthritis. Dermatol. Therapy (2004) 17:364-375.
   Google Scholar
• AMICHAI B: Psoriasis of the glans penis in a child successfully treated with Elidel® (pimecrolimus) cream. J. Eur. Acad. Dermatol. Venereol. (2004) 18:742-743.
   PubMed Web of Science ®Google Scholar
• TAN JKL, MORNEAU K, FUNG K: Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J. Am. Acad. Dermatol. (2005) 52:738-739.
   PubMedGoogle Scholar
• BARR J, FRIEDMAN A: Use of imiquimod and pimecrolimus cream in the treatment of acne keloidalis nuchae. J. Am. Acad. Dermatol. (2005) 52:P64.
   Google Scholar
• CRAWFORD KM, RUSS B, BOSTROM P: Pimecrolimus for treatment of acne rosacea. Skinmed (2005) 4:147-150.
   PubMedGoogle Scholar
• CHU C-Y: The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br. J. Dermatol. (2005) 152:396-399.
   PubMed Web of Science ®Google Scholar
• GORMAN CR, WHITE SW: Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch. Dermatol. (2005) 141:1168.
   Google Scholar
• ZABAWSKI E: Treatment of cutaneous lupus with ElidelTM. Dermatology Online J. (2002) 8:25.
   PubMedGoogle Scholar
• TLACUILO-PARRA A, GUEVARA-GUTIERREZ E, GUTIERREZ-MURILLO F et al.: Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (2005) 44:1564-1568.
   PubMed Web of Science ®Google Scholar
• KREUTER A, GAMBICHLER T, BREUCKMANN F et al.: Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. (2004) 51:407-410.
   PubMed Web of Science ®Google Scholar
• ALMEIDA HL Jr, OLIVEIRA FILHO UL: Topical pimecrolimus is an effective treatment for balanitis circinata erosive. Int. J. Dermatol. (2005) 44:888-889.
   Google Scholar
• DAVATCHI F: New and innovative therapies for Behcet’s disease. APLAR J. Rheumatol. (2004) 7:141-145.
   Google Scholar
• LIM SJ, LOVE EW: Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J. Drugs Dermatol. (2004) 3:563-564.
   PubMedGoogle Scholar
• LONSDALE-ECCLES AA, VELANGI S: Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br. J. Dermatol. (2005) 153:390-394.
   PubMedGoogle Scholar
• ESQUIVEL-PEDRAZA L, FERNÁNDEZ-CUEVAS L, ORTÍZ-PEDROZA G, REYES-GUTIÉRREZ E, OROZCO-TOPETE R: Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br. J. Dermatol. (2004) 150:771-773.
   PubMed Web of Science ®Google Scholar
• MATTSSON U, JONTELL M, HOLMSTRUP P: Oral lichen planus and malignant transformation: is a recall of patients justified? Crit. Rev. Oral Biol. Med. (2002) 13:390-396.
   PubMedGoogle Scholar
• GOLDSTEIN AT, MARINOFF SC, CHRISTOPHER K: Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J. Reprod. Med. (2004) 49:778-780.
   PubMed Web of Science ®Google Scholar
• ARICAN O, CIRALIK H, SASMAZ S: Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J. Dermatol. (2004) 31:1014-1017.
   PubMed Web of Science ®Google Scholar
• BOMS S, GAMBICHLER T, FREITAG M, ALTMEYER P, KREUTER A: Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatology (2004) 4:14.
   PubMedGoogle Scholar
• GOLDSTEIN AT, MARINOFF SC, CHRISTOPHER K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J. Pediatr. Adolesc. Gynecol. (2004) 17:35-37.
   PubMedGoogle Scholar
• GRIMES PE: New insights and new therapies in vitiligo. JAMA (2005) 293:730-735.
   PubMed Web of Science ®Google Scholar
• COSKUN B, SARAL Y, TURGUT D: Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur. J. Dermatol. (2005) 15:88-91.
   PubMed Web of Science ®Google Scholar
• OSTOVARI N, PASSERON T, LACOUR JP, ORTONNE JP: Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch. Dermatol. (2006) 142:252-253.
   PubMed Web of Science ®Google Scholar
• OJI V, BELJAN G, BEIER K, TRAUPE H, LUGER TA: Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. (2005) 153:1067-1068.
   PubMed Web of Science ®Google Scholar
• THACI D, PÄTZOLD S, SCHWANNER S, SPIETH K, RUNNE U, KAUFMANN R: Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J. Eur. Acad. Dermatol. Venereol. (2004) 18(Suppl 2):160-161.
   Google Scholar
• SCHMOOK T, KRAFT J, BENNINGHOFF B, et al.: Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant. (2005) 36:87-88.
   PubMed Web of Science ®Google Scholar
• ZIEMER M, GRUHN M, THIELE JJ, ELSNER P: Treatment of extensive chronic cutaneous graft-versus-hoist disease in an infant with topical pimecrolimus. J. Am. Acad. Dermatol. (2004) 50:946-948.
   PubMedGoogle Scholar
• NEUMAN DL, FARRAR JE, MORESI JM, VOGELSANG GB, HIGMAN MA: Toxic absorption of pimecrolimus in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant. (2005) 36:919-920.
   Google Scholar
• KUS S, INCE U: Lichen striatus in an adult patient treated with pimecrolimus. J. Eur. Acad. Dermatol. Venereol. (2006) 20:341-362.
   Google Scholar
• ALMEIDA HL Jr: Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int. J. Dermatol. (2005) 44:343-344.
   Google Scholar
• LEE HW, JEONG YI, CHOI JC et al.: Two cases of teleangiectasia macularis eruptive perstans demonstrated by immunohistochemistry for c-kit (CD 117). J. Dermatol. (2005) 32:817-820.
   Google Scholar
• ALMEIDA HL Jr: Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J. Am. Acad. Dermatol. (2005) 53:357-358.
   Google Scholar
• SULI DJ, HARFORD R, O’NEILL JT: Discrete popular form of lichen myxedematosus: a case report and review of the literature. Cutis. (2005) 75:105-112.
   Google Scholar
• BÖHM M, BONSMANN G, LUGER TA: Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br. J. Dermatol. (2004) 150:519-520.
   Google Scholar
• RIGOPOULOS D, PRANTSIDIS A, CHRISTOFIDOU E, IOANNIDES D, GREGORIOU S, KATSAMBAS A: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br. J. Dermatol. (2005) 152:1364-1365.
   PubMedGoogle Scholar
• LEE HW, LEE MW, CHOI JH, MOON KC, KOH JK: Annular elastolytic giant cell granuloma in an infant: improvement after treatment with oral transilast and topical pimecrolimus. J. Am. Acad. Dermatol. (2005) 53(Suppl. 2):S244-S246.
   Google Scholar
• HAFNER C, HOHENLEUTNER U, BABILAS P, LANDTHALER M, VOGT T: Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology (2006) 213:163-165.
   Google Scholar
• SACKETT DL, ROSENBERG WM: The need for evidence-based medicine. J. R. Soc. Med. (1995) 88:620-624.
   PubMed Web of Science ®Google Scholar